학술논문
Zanubrutinib in relapsed/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study
Document Type
Article
Author
Source
In Blood 26 May 2022 139(21):3148-3158
Subject
Language
ISSN
0006-4971